You are here: Industry Insights > gene therapy

News List

Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates firstwordpharma
July 15, 2021
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it has entered into a lease agreement to develop a 163,000 square foot manufacturing facility in Fremont, California.
Thermo Fisher supports gene developers with new AAV manufacturing solutions cphi-online
July 12, 2021
Thermo Fisher Scientific has expanded its gene therapy portfolio to include a new media panel, gene kit and advanced purification resins to support gene therapy developers seeking to rapidly and efficiently scale adeno-associated viral (AAV) production.
Thermo Fisher Scientific Expands Gene Therapy Portfolio contractpharma
July 08, 2021
Thermo Fisher Scientific has unveiled a new set of solutions to support adeno-associated viral (AAV) manufacturing.
Pig Study Could Lead to Gene Therapy to Prevent Heart Failure drugs
July 02, 2021
A gene therapy aimed at freeing the heart's capacity for self-repair has shown early promise in an animal study.
BioMarin resubmits haemophilia A gene therapy to the EMA pharmatimes
June 30, 2021
BioMarin has resubmitted a marketing authorisation application (MAA) for its haemophilia A gene therapy valoctocogene roxaparvovec to the European Medicines Agency (EMA), the company announced 28th.
Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON prnasia
June 29, 2021
Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases, announced that the first patient has been dosed in G.O.L.D. clinical trial for the treatment of ...
Patient access to gene therapies for cancer likely to increase in the next decade: GlobalData expresspharma
June 29, 2021
These therapies are expected to eliminate the need for further treatments and reduce the cost of disease management.
Biogen’s inherited eye disease gene therapy misses the mark in late-stage trial pharmatimes
June 17, 2021
Biogen has announced that a late-stage trial of its gene therapy timrepigene emparvovec did not meet its primary and key secondary endpoints in patients with the rare inherited eye disease choroideremia.
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder firstwordpharma
June 11, 2021
Codexis, Inc.,today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited for the research and development of an additional gene therapy for a lysosomal storage disorder bringing
Elicera Therapeutics' new issue heavily oversubscribed firstwordpharma
June 10, 2021
Elicera Therapeutics announced today that the Company's issue of units of approximately SEK 52 million prior to the planned listing on the Nasdaq First North Growth Market was subscribed for approximately 171 percent spread over about 3 600 subscribers.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page